Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Toxicogenetics in drug development
Autore:
Park, BK; Pirmohamed, M;
Indirizzi:
Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside,England Univ Liverpool Liverpool Merseyside England L69 3GE E, Merseyside,England
Titolo Testata:
TOXICOLOGY LETTERS
fascicolo: 1-3, volume: 120, anno: 2001,
pagine: 281 - 291
SICI:
0378-4274(20010331)120:1-3<281:TIDD>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
MICROSOMAL EPOXIDE HYDROLASE; TOXIC EPIDERMAL NECROLYSIS; CARBAMAZEPINE-HYPERSENSITIVITY; THIOPURINE METHYLTRANSFERASE; DOSE REQUIREMENT; PHARMACOGENETICS; WARFARIN; POLYMORPHISMS; METABOLISM; CYP2C9;
Keywords:
adverse drug reactions; toxicogenetics; pharmacogenetics; single nucleotide polymorphisms;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
50
Recensione:
Indirizzi per estratti:
Indirizzo: Park, BK Univ Liverpool, Dept Pharmacol & Therapeut, POB 147,Ashton St, Liverpool L69 3GE, Merseyside, England Univ Liverpool POB 147,Ashton St Liverpool Merseyside England L69 3GE
Citazione:
B.K. Park e M. Pirmohamed, "Toxicogenetics in drug development", TOX LETT, 120(1-3), 2001, pp. 281-291

Abstract

The major progress made in the understanding of the genetic basis of inter-individual variation in drug response, alongside the rapid advances in technology, provides major new opportunities to ensure the safe introduction of a new chemical entity into clinical practice. In essence, the aim is to get the right drug into the right patient using knowledge of factors that influence both benefit and risk. The stage of the drug development process atwhich genetic analysis needs to be undertaken is dependent on the frequency of the event, and the availability of clinical samples. Thus. common adverse events, or assessment of efficacy, will be feasible for testing in phases I-III. However, when a rare event is being studied, for example idiosyncratic toxicity, prospective analysis becomes impossible. Thus, retrospective studies using available drugs is important as it may provide paradigms for future drug development. Additionally, prospective collection of samples will be important so that rare adverse events identified during phase IV can then be analysed using toxicogenetic approaches. Ultimately, information obtained from toxicogenetics must be included in the Specific Product Characteristics (SPC) and thus formally translated into clinical practice in order to contraindicate the drug in specific patients with a genetically determined susceptibility to drug toxicity. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 06:45:03